Learn about a clinical trial for early Alzheimer’s disease.
What is the goal of this trial?
This trial is testing an investigational drug called MK-2214 in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational drug, MK-2214, and how well it may work to slow the progression of Alzheimer’s disease.
Who can join this clinical trial?
You may be able to join if you are 50-85 years of age and:
● Have mild cognitive impairment or mild dementia due to Alzheimer’s disease
● Have a person (trial partner) who can go with you to specific trial visits and:
➤ Knows you well
➤ Is in regular contact with you
➤ Can answer questions about you
Participants are allowed to continue taking certain medicines for Alzheimer’s disease (including, but not limited to, brexpiprazole, donepezil, rivastigmine, galantamine, and
memantine) as long as the dose has not changed for at least 3 months.
The trial doctor will talk with you about more requirements to join this trial.
What will happen during this clinical trial?
If you qualify and decide to participate, you will be in the trial for about 2.5 years and visit the trial site about once a month.
Participants get the trial drugs, tests, and exams at no cost.
To learn more about this clinical trial, including risks and possible benefits of joining, please contact: 786-772-0510
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
